What is Nanjing Hicin Pharmaceutical Co., Ltd.'s (300584.SZ) StockRank?

MoatMap's StockRank for Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) is 26/100, with a Sell signal. This is a composite score combining Quality (57), Value (18), and Momentum (41) factor ranks across MoatMap's 20,000+ stock universe.

Does Nanjing Hicin Pharmaceutical Co., Ltd. have an economic moat?

Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) has a Quality factor score of 57/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Nanjing Hicin Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Nanjing Hicin Pharmaceutical Co., Ltd. in?

Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300584.SZ

SELLREMOVE

Nanjing Hicin Pharmaceutical Co., Ltd. · Healthcare · China · $612M · Avg Vol: $21M/d

StockRank

P/E (TTM)

84.8x

ROE

3.9%

D/E

0.3x

Dividend %

0.3%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Nanjing Hicin is a small-scale domestic pharmaceutical player in China. It lacks the global scale, regulatory validation, and technological moat required to benefit from the high-conviction CDMO pricing power cycle.

COMPANY DESCRIPTION

Nanjing Hicin Pharmaceutical Co., Ltd. develops, manufactures, and markets chemical active pharmaceutical ingredients (APIs) and finished generic drug formulations. The company's competitive advantage lies in its vertically integrated production model, which ensures cost efficiency and strict quality control across cardiovascular, anti-infective, and digestive therapeutic areas. It operates as a reliable domestic pharmaceutical supplier, navigating China's volume-based procurement policies through cost leadership.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	78M	77M	75M	99M	8.4%
EPS	0.04	0.04	0.05	0.05	9.0%
Shares	120M	120M	120M	120M	0.0%
Debt	26M	40M	47M	42M	17.2%
Equity	140M	146M	151M	156M	3.5%
Op CF	-860,060	4M	9M	12M	80.6%
Inv CF	4M	-20M	-12M	-6M	—
Fin CF	-6M	10M	2M	-2M	—

PRICE (1M)-2.4%

SMA 50SMA 200

$6.12

RSI (14)

71.4

52W High

$12.10

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

4.6%56.0

ROE

3.9%53.2

GP/Assets

36.0%74.8

Op. Margin

12.6%70.8

FCF/Assets

3.6%64.3

Piotroski

—83.4

Int. Cover

8.1x61.3

D/E Ratio

0.27x46.2

Current Ratio

1.07x12.0

Value

P/E (TTM)

84.8x11.2

EV/EBITDA

27.3x13.1

P/FCF

512.8x15.4

P/B

3.5x34.2

P/S

5.5x38.0

Div Yield

0.3%9.0

Momentum

52W High %

51%24.3

RS 6M

-30%42.4

SMA 50/200

0.78x10.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—86.5

Q Growth

16%58.8

FUNDAMENTALS

Market Cap

$612M

P/E (Forward)

29.6x

Gross Margin

79.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300584.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300584.SZ	Nanjing Hicin Pharmaceutical Co., Ltd.(you)	$612M	26	SELL
300485.SZ	Beijing Science Sun Pharmaceutical Co., Ltd.	$634M	26	SELL
002365.SZ	Qianjiang Yongan Pharmaceutical Co., Ltd.	$512M	27	SELL
002793.SZ	Luoxin Pharmaceuticals Group Stock Co., Ltd.	$690M	30	SELL
688247.SS	Sinotherapeutics Inc.	$571M	32	SELL
002728.SZ	Teyi Pharmaceutical Group Co.,Ltd	$671M	32	SELL
688621.SS	Beijing Sun-Novo Pharmaceutical Research Co., Ltd.	$894M	26	SELL
301277.SZ	Newland Pharmaceutical Co., Ltd.	$574M	34	SELL
002038.SZ	Beijing SL Pharmaceutical Co., Ltd.	$893M	28	SELL
002907.SZ	Chongqing Pharscin Pharmaceutical Co., Ltd.	$765M	31	SELL

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%

Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) — Stock Score Summary

Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) has a MoatMap StockRank of 26/100 based on Quality (57/100), Value (18/100), and Momentum (41/100) factor scores. The current signal is SELL. Nanjing Hicin is a small-scale domestic pharmaceutical player in China. It lacks the global scale, regulatory validation, and technological moat required to benefit from the high-conviction CDMO pricing power cycle.

Key Financial Metrics

Price	$6.12
Market Cap	$612M
P/E (TTM)	84.76
P/E (Forward)	29.58
Price/Book	3.51
Return on Equity	3.9%
Return on Invested Capital	4.6%
Debt/Equity	26.54
Gross Margin	79.8%
Operating Margin	12.6%
Revenue Growth	12.4%
Dividend Yield	0.3%
Free Cash Flow	$1M

Nanjing Hicin Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Nanjing Hicin Pharmaceutical Co., Ltd.’s (300584.SZ) StockRank?: MoatMap’s StockRank for Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) is 26/100, with a Sell signal. It is a composite of Quality (57), Value (18), and Momentum (41) factor ranks across MoatMap’s 20,000+ stock universe.
Does Nanjing Hicin Pharmaceutical Co., Ltd. have an economic moat?: Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) has a Quality factor score of 57/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nanjing Hicin Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nanjing Hicin Pharmaceutical Co., Ltd. in?: Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).